[干扰素-β对复发缓解型多发性硬化症患者疾病严重程度的长期影响]

[Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients].

作者信息

Patrucco Liliana, Rojas Juan Ignacio, Cristiano Edgardo

机构信息

Sección de Enfermedades Desmielinizantes, Servicio de Neurología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

出版信息

Rev Neurol. 2010 May 1;50(9):529-32.

PMID:20443171

Abstract

AIM

To investigate the long-term impact of interferon-beta (IFNbeta) therapy on disease severity in relapsing-remitting multiple sclerosis (RRMS) patients.

PATIENTS AND METHODS

We included 210 patients with RRMS and indication for immunomodulatory treatment followed up at least for nine years. We compared between treated and untreated groups: time since the beginning of the disease to reach EDSS 6.0 and time to conversion to secondary progressive multiple sclerosis. Log-rank test was used to compare outcomes between groups, p < 0.05 were considered significant.

RESULTS

160 patients were IFNbeta-treated, 50 untreated. The percentage of patients that converted to SPMS after 9 years of follow-up was 7.1% for treated vs. 21.7% for untreated (p = 0.022; RR = 0.32; 95% CI = 0.13-0.74). About 7.7% for IFNbeta-treated vs. 18.7% of untreated patients reached EDSS 6.0 after the period of follow-up (p = 0.032; RR = 0.4; 95% CI = 0.16-0.95). Mean time to reach EDSS 6.0 was 8.1 years for IFNbeta-treated vs. 5.8 years for untreated patients (p < 0.001).

CONCLUSION

Long term treatment with IFNbeta slows progression in MS measured by EDSS and time to conversion to secondary progressive multiple sclerosis.

摘要

目的

探讨β-干扰素（IFNβ）治疗对复发缓解型多发性硬化症（RRMS）患者疾病严重程度的长期影响。

患者与方法

我们纳入了210例RRMS患者，这些患者有免疫调节治疗指征且随访至少9年。我们比较了治疗组和未治疗组：从疾病开始到扩展残疾状态量表（EDSS）达到6.0的时间以及转化为继发进展型多发性硬化症的时间。采用对数秩检验比较组间结果，p<0.05被认为具有统计学意义。

结果

160例患者接受IFNβ治疗，50例未治疗。随访9年后转化为继发进展型多发性硬化症的患者百分比，治疗组为7.1%，未治疗组为21.7%（p = 0.022；风险比[RR]=0.32；95%置信区间[CI]=0.13 - 0.74）。随访期后，接受IFNβ治疗的患者中有7.7%达到EDSS 6.0，未治疗患者为18.7%（p = 0.032；RR = 0.4；95%CI = 0.16 - 0.95）。达到EDSS 6.0的平均时间，接受IFNβ治疗的患者为8.1年，未治疗患者为5.8年（p<0.001）。